


## SC57666

Cat. No.:	HY-U00129		
CAS No.:	158959-32-1		
Molecular Formula:	C <sub>18</sub> H <sub>17</sub> FO <sub>2</sub> S		
Molecular Weight:	316.39		
Target:	COX		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

### In Vitro

DMSO : ≥ 100 mg/mL (316.07 mM)

\* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.1607 mL	15.8033 mL	31.6066 mL
	5 mM		0.6321 mL	3.1607 mL	6.3213 mL
	10 mM		0.3161 mL	1.5803 mL	3.1607 mL

Please refer to the solubility information to select the appropriate solvent.

### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (7.90 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (7.90 mM); Clear solution

## BIOLOGICAL ACTIVITY

### Description

SC57666 is a selective COX2 inhibitor with an IC<sub>50</sub> of 26 nM.

### IC<sub>50</sub> & Target

COX-2  
26 nM (IC<sub>50</sub>)

### In Vitro

SC57666 inhibits COX2 with an IC<sub>50</sub> of 3.2±0.8 nM in CHO cells stably transfected with human COX isozymes, with 1000 fold or more selectivity over COX1 (IC<sub>50</sub>=6000±1900 nM)<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

SC57666 has been shown to be orally active ( $ED_{50}=1.7$  mpk) in the adjuvant-induced arthritis model. No gastric lesions are observed in mice after 5 h when SC57666 is administered intragastrically at 600 mpk. No intestinal damage is observed in rats after 72 h when SC57666 is administered intragastrically at 200 mpk<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

- [1]. Reitz DB, et al. Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenones are potent and orally active COX2 inhibitors. J Med Chem. 1994 Nov 11;37(23):3878-81.
- [2]. Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA